Cannabinol
A THC degradation product with emerging evidence for sleep and pain
Cannabinol (CBN) is formed when THC oxidizes and degrades over time. It is the first cannabinoid to be isolated from cannabis (1896) and has been heavily marketed as a sleep aid. The clinical evidence for CBN is more limited than marketing suggests, but emerging research supports roles in pain modulation, appetite stimulation, and antibacterial activity.
Primary Receptors & Targets
CBN is a weak partial agonist at CB1 receptors — approximately 10% the potency of THC. This weak CB1 activity may contribute to mild sedative effects, but is unlikely to produce significant psychoactivity at typical consumer doses.
CBN's analgesic effects appear to involve TRPA1 and TRPV2 receptor activation, which are ion channels involved in pain and temperature sensation. A 2019 study found that CBN sensitizes TRPA1 channels in sensory neurons, which may contribute to its pain-modulating effects.
The sedative effects historically attributed to CBN may have been largely due to the terpene profile of aged cannabis rather than CBN itself. Older cannabis preparations that were high in CBN were also typically high in sedating terpenes like myrcene and linalool, which accumulated as the plant material aged. Controlled studies using purified CBN have produced inconsistent sedation results.
Early studies suggested sedation; more recent controlled research has not consistently replicated this. Terpene co-presence may be a confounding factor.
2019 study found CBN + CBD combination more effective than either alone for myofascial pain in rats.
CBN increased food intake in rats similarly to THC without psychoactivity in a 2012 study.
CBN demonstrated antibacterial activity against MRSA in the same 2008 study that identified CBD and CBG as active.
Case reports of topical CBN reducing blistering and pain; no controlled trials.
Evidence levels reflect the current state of clinical and preclinical research. Preliminary evidence does not constitute medical advice. Consult a healthcare provider before using cannabinoids therapeutically.
Archives of Oral Biology
The combination of CBN and CBD was more effective than either cannabinoid alone in reducing myofascial pain sensitivity in a rat model.
Journal of Natural Products
CBN demonstrated activity against MRSA strains resistant to multiple antibiotics, alongside CBD, CBC, and CBG.
Psychopharmacology
CBN increased food intake in rats, suggesting appetite-stimulating properties independent of CB1 psychoactivity.
CBN holds the distinction of being the first cannabinoid ever isolated from cannabis. In 1896, British chemists Thomas Barlow Wood, W.T. Newton Spivey, and Thomas Hill Easterfield isolated a compound from red oil of cannabis that they named cannabinol. Its structure was fully determined in 1940 by Alexander Todd at the University of Manchester. Ironically, CBN — the first cannabinoid isolated — is not directly synthesized by the cannabis plant. It is a degradation product of THC, formed when THC is exposed to oxygen, heat, or UV light over time. Fresh cannabis contains very little CBN; aged or improperly stored cannabis can accumulate significant quantities.
CBN has been aggressively marketed as a "natural sleep aid" and "the sleepy cannabinoid," commanding significant price premiums in the consumer market. This marketing outpaces the science. The primary evidence cited for CBN's sedative effects comes from a 1975 study that found CBN enhanced the sedative effects of THC in human subjects — but this study used CBN in combination with THC, not CBN alone. Subsequent controlled studies using purified CBN have produced inconsistent results. The honest scientific position is that CBN may contribute to sleep effects in combination formulations, but is not a proven standalone sleep aid.